Beigene Ltd (NASDAQ:BGNE)

137.91
Delayed Data
As of 4:00pm ET
 +2.15 / +1.58%
Today’s Change
105.19
Today|||52-Week Range
164.99
-1.68%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$8.0B

Company Description

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Contact Information

BeiGene Ltd.
Zhongguancun Life Science Park
Beijing Beijing 102206
P:861058958000
Investor Relations:

Employees

Shareholders

Other institutional51.44%
Mutual fund holders32.22%
Individual stakeholders28.61%

Top Executives

There are no executives to display.